Missense Mutations in Cancer Predisposing Genes: Can We Make Sense of Them? by Scott, Rodney J & Meldrum, Cliff J
H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(3) 123
Hereditary Cancer in Clinical Practice 2005; 3(3) pp. 123-127
A Ab bs st tr ra ac ct t
In the analysis of genes associated with predispositions to malignancy the causative status of mutations can be made
relatively easily where it is obvious that there is a clear disruption in the coding sequence of the gene. Difficulties
arise, however, if missense mutations are identified, as these are not easily categorised into genetic variants that are
not associated with disease risk or into clearly causative changes that impart a significant risk of disease. 
As more individuals are subject to DNA sequence analysis for the identification of causative changes in genes
associated with cancer predisposition, an increasing number of missense mutations are being identified. Causative
status assignment to missense mutations continues to be problematic especially where no functional assessment
of the alteration can be made. As more information is gathered on missense mutations our predictive ability to
assign significance will improve. 
In this report we review, in broad terms, what measures can be undertaken to categorise missense mutations
into those that are clearly causative, probably causative and most likely not causative.  
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I In nt tr ro od du uc ct ti io on n
There are many facets that need to be considered
when determining whether a missense mutation is
indeed causative or just a common polymorphism that
has no impact on the functional activity of the gene in
question. The definition of a missense mutation is 
‘a single base pair substitution that results in the
translation of a different amino acid at that position’
[1]. This differentiates missense changes from silent
polymorphisms where there is no apparent change in
the protein product of the gene. 
When considering what effect a missense change
may have, several aspects need to be considered. 1) Is
the change associated with a change in polarity of the
corresponding amino acid, and if it is what effects is this
likely to have on the function of the protein? If the change
does not alter the polarity of the amino acid, is there any
observable effect (i.e. change in function)? 2) How
common is the change in the population? Do different
populations harbour different frequencies of the change,
and if so are these associated with disease? 3) Does the
missense change occur in association with another
change, and if so is it clearly deleterious (e.g. a nonsense
change), other missense changes or more cryptic
changes that relate to gene modification? 
In determining the effect of missense changes
a number of avenues of investigation can be followed.
These include the association of missense changes with
disease (segregation analysis), the evolutionaryH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(3) 124
Rodney J. Scott, Cliff J. Meldrum
conservation of the region within the gene and the
presence of loss of heterozygosity in tumour samples
from patients harbouring the change. 
M Mi is ss se en ns se e   m mu ut ta at ti io on n   f fr re eq qu ue en nc cy y   
i in n   d di if ff fe er re en nt t   i in nh he er ri it te ed d   p pr re ed di is sp po os si it ti io on ns s
In relation to inherited predispositions to cancer there
have been a considerable number of missense mutations
submitted to the Human Genome Database as shown in
Table 1. The number to date reflects a minor proportion
but nevertheless some trends are emerging with respect
to the likelihood of identifying a missense change in genes
associated with predispositions to malignancy. On
examination of Table 1 there appears to be a significant
difference between the number of missense changes
identified in the APC gene compared to any of the other
genes. This is most likely due to there being a selection
bias for causative mutations identified by the protein
truncation test (PTT), which has been used by many
groups to identify mutations in exon 15 of the APC gene
due to its large size (~6,800 bp). A second reason for
the bias comes from understanding the biology of the
APC gene, which suggests that missense mutations are
unlikely to be associated with disease. Currently, the
primary function of the APC gene appears to be the
regulation of β-catenin. The APC protein harbours
a series of β-catenin binding sites and β-catenin binding
and down-regulation domains. A single missense
mutation is unlikely to knock out this function since there
are multiple domains which harbour these functional
moieties [2]. Support of this notion comes from studies
that indicate that the site of the primary mutation in the
APC gene appears to result in a selective advantage for
particular types of mutation in the remaining wild type
allele [2]. However, there is little information as to whether
missense mutations in the APC gene also result in selective
advantages. The difference in frequencies of missense
mutations in the other genes listed in Table 1 can also be
attributed to the methods employed to analyse the
respective genes. For example, both BRCA1 and BRCA2
contain large exons that comprise several thousand base
pairs, which similar to APC lend themselves for analysis
by the PTT. This test can only recognise changes that result
in premature termination codons and cannot be used to
identify any missense mutation. Therefore, the relative
percentage of missense changes will be lower than that
observed in genes screened by other methodologies,
which interrogate DNA more specifically (such as direct
sequencing or denaturing high performance liquid
chromatography). This is observed in hereditary
nonpolyposis colorectal cancer (HNPCC) and Peutz
Jeghers Syndrome (PJS), where there is a greater
proportion of missense mutations identified in the three
genes listed in Table 1. In conclusion, the likelihood of
identifying missense mutations in genes associated with
inherited predispositions to cancer is influenced by how
the majority of mutation analyses are performed and to
a lesser extent by the function of the resultant protein
product. 
C Ca an n   m mi is ss se en ns se e   m mu ut ta at ti io on ns s   b be e   c cl la as ss si if fi ie ed d   
i in n   t th he e   a ab bs se en nc ce e   o of f   f fu un nc ct ti io on na al l   s st tu ud di ie es s? ?   
In the absence of functional studies a prediction,
with a relatively high degree of accuracy, can be made
if a series of circumstantial evidence can be taken into
account. 
Neutral variants: Evidence is accumulating that
suggests that there are approximately 3 million single
nucleotide polymorphisms (SNPs) spread across the
entire human genome, some of which would be
described as missense mutations when they occur within
coding sequences of DNA. Such changes can be
deemed to be neutral variants if they occur frequently
in the general population and cannot be linked to
disease. One such example is the D1822V change in
the APC gene, which was initially believed to be
causative but in population studies occurred frequently
and was not linked to an increased likelihood of
colorectal cancer. Indeed in our own studies the
D1822V change was identified at a frequency of
approximately 40% in an unselected population [3].
Furthermore, to support this evidence, extensive family
studies failed to reveal any segregation with disease.
Together, this information can be used to assign causal
status of the missense mutation. 
In contrast, some missense variants will, using this
approach, be considered as causal. For example,
T Ta ab bl le e   1 1. .   Percentage of missense mutation variants identified in the
Human Genome Database (to May 2005) [7]
D Di is se ea as se e/ /m mu ut ta at ti io on n F Fr re eq qu ue en nc cy y   o of f   m mi is ss se en ns se e   M Mu ut ta at ti io on n   V Va ar ri ia at ti io on ns s
Breast Cancer 15.1% BRCA1 (99) 
13.9% BRCA2 (62) 
FAP 3.1% APC (19) 
HNPCC 27.4% hMLH1 (102) 
24.6% hMSH2 (75) 
32.9% hMSH6 (23) 
PJS 19.7% LKB1/STK11 (23) 
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changes that are only observed in rare susceptibilities
to disease and are not observed in population-based
studies are highly suggestive of causality. One such
change, for example, is the L285P missense mutation
identified in a PJS family that is rare and segregates
exclusively with disease. 
This approach, however, is not absolutely reliable.
It is possible that mutations exist which fulfil the above
criteria but cannot be specifically assigned as
a causative change. In one Birtt-Hogg-Dube family the
affected proband harboured a S128R change, which
appeared to be responsible for the patient’s renal cell
cancer but when the father (also suffering from renal
cell cancer) of the proband was tested for this change
the result was negative. Instead, the healthy mother of
the individual harboured the change, suggesting either
that the change was neutral or that it was associated
with highly variable disease penetrance. 
C Co o- -o oc cc cu ur rr re en nc ce e   i in n   t tr ra an ns s   
w wi it th h   a an no ot th he er r   d de el le et te er ri io ou us s   m mu ut ta at ti io on n
A missense mutation may be classified as neutral
if it is observed in trans with another causative
mutation in the germline. This assumes that
homozygosity for a causative mutation or compound
heterozygosity for two causative changes in any of the
common genes associated with cancer predisposition
are likely to be lethal conditions. To determine that
a missense mutation is in trans with another
deleterious mutation requires access to suitable
databases that contain full sequencing data on the
gene in question. At present, these are limited and
probably one of the best sources for such information
in relation to cancer genetics is that of Myriad
Genetics
TM, which has sufficient information to assess
such changes in BRCA1 and possibly BRCA2. 
A single observation of co-occurrence of a missense
mutation with a causative mutation is sufficient to
classify a missense variation as non-causative. However,
classification of missense mutations as causative by this
method is more problematic requiring the study of large
numbers of individuals to obtain a significant measure
of non-occurrence. In summary, this approach to
assessing the relevance of a missense mutation is likely
to result in the classification of a number of missense
mutations as non-causative but overall there is a low
power to show causation. 
E Ev vo ol lu ut ti io on na ar ry y   c co on ns se er rv va at ti io on n
Evolutionary conservation represents possibly
a relatively easy and effective measure by which to
assess the causality of missense changes. The
advantage of this approach is that it can be applied to
every missense change but, and this cannot be
overstated, only indirectly relates to disease risk and
as such always requires additional information to
provide any reliability in prediction. 
In using this approach for missense change
evaluation it is not sufficient to only compare the
human sequence to one other species. It is better to
undertake multiple homologue comparison as the
further in evolutionary time apart the sequence
similarities are the more likely the sequence is
absolutely required for the function of the encoded
protein. A lack of observed evolutionary change may
indicate insufficient time for change rather than
sequence conservation through evolution. One
significant drawback to this approach is the availability
of sequence information for a large enough variety of
organisms, as without it the reliability of the result is
likely to be lower than that required. 
When using this approach, it must be remembered
that this method of prediction will only be effective for
conserved sequences and if the sequence change
occurs in a segment of the gene that is not crucial for
its function then it will be unlikely that this approach
will be useful in determining causality. 
F Fu un nc ct ti io on n
The evaluation of a variant’s effect on protein and
cellular function probably represents the ultimate
assessment for the determination of causality. Any effect
of a missense mutation that results in the abrogation
or loss of function of the encoded protein is most likely
to be causative. However, some caution needs to be
taken in extrapolating functional changes to disease
states. The relationship of a particular protein function
to disease needs to be taken into account. 
Missense changes that are different to those
reported to alter protein function but occur at sites that
have been reported for other changes cannot
automatically be assumed to be causative unless
functional studies have been undertaken. As mentioned
above, not all functional assays, however, may be
related to cancer causation and as such care needs to
be taken in interpreting some alterations in protein
activity. Examples of this occur in the transcriptional
activation domains within the genes BRCA1, BRCA2
and the mismatch repair capacity of hMLH1 or hMSH2. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(3) 126
One of the major drawbacks in the assessment of
protein function is the lack of functional assays for
a significant proportion of genes associated with
predispositions to cancer. Alternative methods are being
developed to assess the role of missense changes in
disease and several new algorithms are being
developed for predictive purposes [4]. At the time of
writing this review a new SNPWEB is being developed
at the UCSF (the server is currently under construction).
The aim of this web base is to determine how SNPs
affect protein domain structures by comparing the wild
type 3D protein model to that containing the SNP [4].
The result of this analysis provides a prediction of the
effect of the SNP on the 3D model and how this may
relate to a change in protein function. 
In conclusion, functional studies that incorporate
variations are probably the best evidence for causality,
but since functional analyses are often difficult to
develop it is more likely that appropriate algorithms
will be developed that will have a high degree of
predictability and that these will be used with an
increasing frequency in the future. 
C Cu ur rr re en nt t   p pr ra ac ct ti ic ca al l   a ap pp pr ro oa ac ch he es s   t to o   a as ss si ig gn ni in ng g
c ca au us sa al l   s st ta at tu us s   t to o   m mi is ss se en ns se e   m mu ut ta at ti io on ns s
From the above description of what can be done to
determine the causality of missense mutations it is
obvious that a variety of approaches can be taken in
determining whether or not they are linked to disease.
The best approach would be to use all of the
approaches together to obtain a result that has high
predictive power. Unfortunately, not all of the approaches
are feasible in all situations and some of them await
continued refinement. The following example from
Thompson et al [5] indicates how a combined approach
can lead to an accurate prediction of causality. 
The D2723H missense mutation in BRCA2 has
been reported 24 times in the breast cancer
information core (BIC) database but has never been
shown to be a proven deleterious mutation. 
However, the original data in the BIC database
suggest at best the odds in favour of causality being
at 2:1. Complete cosegregation analysis with disease
using 10 pedigrees results in odds in favour of causality
being 13,731:1. Combining the odds of both of these
factors results in a change in favour of causality to
57,000:1 [5]. When this information is taken together
with the knowledge that the change occurs in
a conserved region of the genome and that this change
has been associated with mis-localisation of the protein
[6] which results in a reduced DNA repair capacity, it
is almost certain that this change is causative. 
This approach clearly demonstrates the power of
applying an integrated approach to determining the
causality of a given missense mutation. There are,
however, significant improvements that need to be
made so that the causality of a missense change can
be readily estimated without searching in several
different databases and the requirement of functional
studies. 
In summary, Goldgar et al [6] have proposed an
integrated approach to the classification of missense
mutations incorporating the following points: 
1) first step in developing an integrated approach
– more data required to refine model, 
2) classification based on: 
– complete neutrality OR causality comparable to
known mutations (i.e nothing in between), 
3) classification ideally based on clinical observation
since directly related to cancer risk and more
quantifiable, 
4) of genomic data evolutionary conservation was
a useful predictive factor severity of amino acid
substitution data was not, 
5)  provides a standard system for evaluation of
unclassified variants, 
6) avoids over-reliance on any single method. 
Further refinement is required to optimise this
approach and an outcome of the approach taken
above has been that the methods already used, which
include cosegregation, family history, pathology and
other clinical observations, are probably the most
useful. Quantitation of the above should allow better
standardisation and comparison and, finally, genomic
data can strengthen the argument for or against but
is not usually sufficient stand-alone evidence. 
Whatever approach is used it is clear that at the
present time a more systematic approach to the
interpretation of missense mutations in genes
predisposing to cancer is required. This should include
a system for estimating odds ratios for segregation studies
so that comparisons can be made between studies and
reports of missense changes. This could extend to the
inclusion of these estimates in databases that report
missense changes, thus allowing the combination of
various studies potentially leading to classification of
a missense change when significance is reached. 
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